Brian Carey

Dr. Brian Carey

Virology, United States Army Medical Research Institute of Infectious Diseases, Frederick, Colorado, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
JGJoseph Golden
Joseph Golden
CCCurtis R. Cline
Curtis R. Cline
XZXiankun Zeng
Xiankun Zeng
AGAura R. Garrison
Aura R. Garrison
BCBrian Carey
Brian Carey
JHJay Hooper
Jay Hooper
The emergence of SARS-CoV-2 has created an international health crisis, and small animal models mirroring SARS-CoV-2 human disease are essential for medical countermeasure (MCM) development. Mice are refractory to SARS-CoV-2 infection owing to low-affinity binding to the murine angiotensin-converting enzyme 2 (ACE2) protein. Here, we evaluated the pathogenesis of SARS-CoV-2 in male and female mice expressing the human ACE2 gene under the control of the keratin 18 promoter (K18). In contrast to nontransgenic mice, intranasal exposure of K18-hACE2 animals to 2 different doses of SARS-CoV-2 resulted in acute disease, including weight loss, lung injury, brain infection, and lethality. Vasculitis was the most prominent finding in the lungs of infected mice. Transcriptomic analysis from lungs of infected animals showed increases in transcripts involved in lung injury and inflammatory cytokines. In the low-dose challenge groups, there was a survival advantage in the female mice, with 60% surviving infection, whereas all male mice succumbed to disease. Male mice that succumbed to disease had higher levels of inflammatory transcripts compared with female mice. To our knowledge, this is the first highly lethal murine infection model for SARS-CoV-2 and should be valuable for the study of SARS-CoV-2 pathogenesis and for the assessment of MCMs.

29 September 2017 in Viruses
Verified
Journal Article
Open access
PDF file
LLLindsay Lundberg
Lindsay Lundberg
BCBrian Carey
Brian Carey
KKKylene Kehn-Hall
Kylene Kehn-Hall
Venezuelan equine encephalitis virus (VEEV) is a New World alphavirus that is vectored by mosquitos and cycled in rodents. It can cause disease in equines and humans characterized by a febrile illness that may progress into encephalitis. Like the capsid protein of other viruses, VEEV capsid is an abundant structural protein that binds to the viral RNA and interacts with the membrane-bound glycoproteins. It also has protease activity, allowing cleavage of itself from the growing structural polypeptide during translation. However, VEEV capsid protein has additional nonstructural roles within the host cell functioning as the primary virulence factor for VEEV. VEEV capsid inhibits host transcription and blocks nuclear import in mammalian cells, at least partially due to its complexing with the host CRM1 and importin α/β1 nuclear transport proteins. VEEV capsid also shuttles between the nucleus and cytoplasm and is susceptible to inhibitors of nuclear trafficking, making it a promising antiviral target. Herein, the role of VEEV capsid in viral replication and pathogenesis will be discussed including a comparison to proteins of other alphaviruses.

1 September 2018 in Antiviral Research
Verified
Journal Article
Closed access
LLLindsay Lundberg
Lindsay Lundberg
ABAshwini Brahms
Ashwini Brahms
IHIdris Hooper
Idris Hooper
BCBrian Carey
Brian Carey
Lim Chih-ChenLim Chih-Chen
Lim Chih-Chen
KKKylene Kehn-Hall
Kylene Kehn-Hall

1 March 2019 in Antiviral Research
Verified
Journal Article
Closed access
BCBrian Carey
Brian Carey
Allison BakovicAllison Bakovic
Allison Bakovic
VCVictoria Callahan
Victoria Callahan
ANAarthi Narayanan
Aarthi Narayanan
KKKylene Kehn-Hall
Kylene Kehn-Hall

17 November 2024 in npj Vaccines
Verified
Journal Article
Open access
PDF file
BCBrian Carey
Brian Carey
SYShuiqing Yu
Shuiqing Yu
JGJillian Geiger
Jillian Geiger
CYChengjin Ye
Chengjin Ye
LHLouis M. Huzella
Louis M. Huzella
Jens H. KuhnJens H. Kuhn
Jens H. Kuhn
Lassa virus (LASV) is a rodent-borne mammarenavirus that causes tens to hundreds of thousands of human infections annually in Western Africa. Approximately 20% of these infections progress to Lassa fever (LF), an acute disease with case–fatality rates from ≈20–70%. Currently, there are no approved vaccines or specific therapeutics to prevent or treat LF. The LASV genome consists of a small (S) segment that has two genes, GP and NP, and a large (L) segment that has two genes, L and Z. In both segments, the two genes are separated by non-coding intergenic regions (IGRs). Recombinant LASVs (rLASVs), in which the L segment IGR was replaced with the S segment IGR or in which the GP gene was codon-deoptimized, lost fitness in vitro, were highly attenuated in vivo, and, when used as vaccines, protected domesticated guinea pigs from otherwise lethal LASV exposure. Here, we report the generation of rLASV/IGR-CD, which includes both determinants of attenuation and further enhances the safety of the vaccine compared with its predecessors. rLASV/IGR-CD grew to high titers in Vero cells, which are approved for human vaccine production, but did not cause signs of disease or pathology in guinea pigs. Importantly, guinea pigs vaccinated with rLASV/IGR-CD were completely protected from disease and death after a typically lethal exposure to wild-type LASV. Our data support the development of rLASV/IGR-CD as a live-attenuated LF vaccine with stringent safety features.

2 March 2021 in Pathogens
Verified
Journal Article
Open access
PDF file
BCBrian Carey
Brian Carey
VCVictoria Callahan
Victoria Callahan
IAIvan V Akhrymuk
Ivan V Akhrymuk
NBNishank Bhalla
Nishank Bhalla
WZWeidong Zhou
Weidong Zhou
KKKylene Kehn-Hall
Kylene Kehn-Hall
Alphaviruses are a genus of the Togaviridae family and are widely distributed across the globe. Venezuelan equine encephalitis virus (VEEV) and eastern equine encephalitis virus (EEEV), cause encephalitis and neurological sequelae while chikungunya virus (CHIKV) and Sindbis virus (SINV) cause arthralgia. There are currently no approved therapeutics or vaccines available for alphaviruses. In order to identify novel therapeutics, a V5 epitope tag was inserted into the N-terminus of the VEEV E2 glycoprotein and used to identify host-viral protein interactions. Host proteins involved in protein folding, metabolism/ATP production, translation, cytoskeleton, complement, vesicle transport and ubiquitination were identified as VEEV E2 interactors. Multiple inhibitors targeting these host proteins were tested to determine their effect on VEEV replication. The compound HA15, a GRP78 inhibitor, was found to be an effective inhibitor of VEEV, EEEV, CHIKV, and SINV. VEEV E2 interaction with GRP78 was confirmed through coimmunoprecipitation and colocalization experiments. Mechanism of action studies found that HA15 does not affect viral RNA replication but instead affects late stages of the viral life cycle, which is consistent with GRP78 promoting viral assembly or viral protein trafficking.